A Phase II Study of the Gamma Secretase Inhibitor RO4929097 [RG 4733] in Previously Treated Metastatic Pancreas Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs RG 4733 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jul 2012 Planned End Date changed from 1 Nov 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.